RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo (original) (raw)

• Martinez J et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002; 110: 563–574.
  Article CAS PubMed Google Scholar
• Elbashir SM et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494–498.
  Article CAS PubMed Google Scholar
• Hannon GJ . RNA interference. Nature 2002; 418: 244–251.
  Article CAS PubMed Google Scholar
• Xia H, Mao Q, Paulson HL, Davidson BL . siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006–1010.
  Article CAS PubMed Google Scholar
• McCaffrey AP et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639–644.
  Article CAS PubMed Google Scholar
• Jacque JM, Triques K, Stevenson M . Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435–438.
  Article CAS PubMed Google Scholar
• Coburn GA, Cullen BR . Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 2002; 76: 9225–9231.
  Article CAS PubMed PubMed Central Google Scholar
• Kapadia SB, Brideau-Andersen A, Chisari FV . Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003; 100: 2014–2018.
  Article CAS PubMed PubMed Central Google Scholar
• Zhang L et al. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003; 303: 1169–1178.
  Article CAS PubMed Google Scholar
• Brummelkamp TR, Bernards R, Agami R . A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550–553.
  Article CAS PubMed Google Scholar
• Boussif O et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297–7301.
  Article CAS PubMed PubMed Central Google Scholar
• Aigner A et al. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Therapy 2002; 9: 1700–1707.
  Article CAS PubMed Google Scholar
• Kichler A . Gene transfer with modified polyethylenimines. J Gene Med 2004; 6 (Suppl 1): S3–S10.
  Article CAS PubMed Google Scholar
• Wagner E, Kircheis R, Walker GF . Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. Biomed Pharmacother 2004; 58: 152–161.
  Article CAS PubMed Google Scholar
• Dheur S et al. Polyethylenimine but not cationic lipid improves antisense activity of 3′-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev 1999; 9: 515–525.
  Article CAS PubMed Google Scholar
• Bologna JC, Dorn G, Natt F, Weiler J . Linear polyethylenimine as a tool for comparative studies of antisense and short double-stranded RNA oligonucleotides. Nucleosides Nucleotides Nucleic Acids 2003; 22: 1729–1731.
  Article CAS PubMed Google Scholar
• Tzahar E et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276–5287.
  Article CAS PubMed PubMed Central Google Scholar
• Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712.
  Article CAS PubMed Google Scholar
• McKeage K, Perry CM . Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62: 209–243.
  Article CAS PubMed Google Scholar
• Bookman MA et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283–290.
  Article CAS PubMed Google Scholar
• Choudhury A et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004; 108: 71–77.
  Article CAS PubMed Google Scholar
• Yang G et al. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004; 279: 4339–4345.
  Article CAS PubMed Google Scholar
• Abuharbeid S et al. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun 2004; 321: 403–412.
  Article CAS PubMed Google Scholar
• Hsieh SS, Malerczyk C, Aigner A, Czubayko F . ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int J Cancer 2000; 86: 644–651.
  Article CAS PubMed Google Scholar
• Zaric V et al. Effective polyethylenimine-mediated gene transfer into human endothelial cells. J Gene Med 2004; 6: 176–184.
  Article CAS PubMed Google Scholar
• Takei Y et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365–3370.
  Article CAS PubMed Google Scholar
• Maeda H et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271–284.
  Article CAS PubMed Google Scholar
• Czubayko F et al. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Therapy 1997; 4: 943–949.
  Article CAS PubMed Google Scholar
• Juhl H, Downing SG, Wellstein A, Czubayko F . HER-2/neu is rate-limiting for ovarian cancer growth: Conditional depletion of HER-2/neu by ribozyme targeting. J Biol Chem 1997; 272: 29482–29486.
  Article CAS PubMed Google Scholar
• Song E et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347–351.
  Article CAS PubMed Google Scholar
• Filleur S et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003; 63: 3919–3922.
  CAS PubMed Google Scholar
• Aigner A et al. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 2001; 20: 2101–2111.
  Article CAS PubMed Google Scholar
• Aigner A et al. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 2001; 92: 510–517.
  Article CAS PubMed Google Scholar
• Aigner A et al. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002; 21: 5733–5742.
  Article CAS PubMed Google Scholar
• Aigner A, Ray PE, Czubayko F, Wellstein A . Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem Cell Biol 2002; 117: 1–11.
  Article CAS PubMed Google Scholar